News from nordic nanovector A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 21, 2022, 10:43 ET Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R Follicular Lymphoma

Nordic Nanovector ASA (OSE: NANOV) today provides an update following its comprehensive review and independent data evaluation of PARADIGME, its...

Jun 10, 2022, 04:36 ET Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting

Nordic Nanovector ASA (OSE: NANOV) announces an update from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® (177Lu lilotomab satetraxetan) in ...

Jun 02, 2022, 01:24 ET Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment

Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in...

May 20, 2022, 04:16 ET Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors

Reference is made to the minutes from Nordic Nanovector ASA's (the "Company") (OSE: NANOV) annual general meeting held on 28 April 2022 in Oslo,...

May 13, 2022, 01:52 ET Nordic Nanovector ASA: Results for the First Quarter 2022

Nordic Nanovector ASA (OSE: NANOV) announces its results for the first quarter 2022. A presentation by Nordic Nanovector's senior management team...

May 06, 2022, 10:04 ET Nordic Nanovector ASA: Invitation to First Quarter 2022 Results Presentation and Webcast

Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the first quarter 2022 on Friday, 13 May 2022. A presentation by...

May 03, 2022, 03:00 ET Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin® in Combination with the PARP-inhibitor Olaparib

Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune...

Apr 28, 2022, 11:40 ET Nordic Nanovector ASA: The Annual General Meeting held

The Annual General Meeting (the "AGM") of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was held today on 28 April 2022 in Oslo, Norway. All...

Apr 06, 2022, 05:58 ET Nordic Nanovector ASA - Notice of Annual General Meeting on 28 April 2022

Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 April 2022, at 14:00 hours CEST at Advokatfirmaet Selmer, ...

Apr 06, 2022, 05:22 ET Nordic Nanovector ASA publishes Annual Report 2021

On 5 April 2022, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2021. The Company's 2021 Annual...

Apr 06, 2022, 02:59 ET Nordic Nanovector ASA Announces Proposed Board Changes - Former Algeta CEO Thomas Ramdahl nominated to Join Board of Directors

Nordic Nanovector ASA (OSE: NANOV) announces that its Nomination Committee has nominated Dr Thomas Ramdahl for election as a Non-executive Director...

Mar 23, 2022, 04:07 ET Nordic Nanovector ASA - Mandatory notification of trade - settlement of PSUs

Reference is made to the stock exchange announcement made by Nordic Nanovector ASA's (OSE: NANOV) (the "Company") on 31 January 2019, regarding...

Mar 11, 2022, 01:17 ET Nordic Nanovector ASA - allocation of PSUs

The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") has on 10 March 2022 decided to grant 934,000 Performance...

Mar 09, 2022, 01:46 ET Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting

Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune...

Mar 01, 2022, 01:24 ET Nordic Nanovector ASA: Results for the Fourth Quarter and Full Year 2021

Nordic Nanovector ASA (OSE: NANOV) announces its results for the fourth quarter and full year 2021. A live webcast presentation by Nordic...

Feb 22, 2022, 04:17 ET Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2021 Results Presentation and Webcast

Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the fourth quarter and full year 2021 on Tuesday, 1 March 2022. A...

Feb 14, 2022, 04:33 ET Nordic Nanovector ASA: Extraordinary general meeting held

Nordic Nanovector ASA (the "Company") announces that an extraordinary general meeting ("EGM") in the Company was held today at the Company's offices...

Jan 07, 2022, 13:43 ET Nordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin® (177Lu...

Dec 23, 2021, 01:47 ET Nordic Nanovector ASA: Financial Calendar for 2022

Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune...

Dec 16, 2021, 02:16 ET Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer

Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune...

Dec 08, 2021, 10:47 ET Nordic Nanovector to Present at DNB's 12th Nordic Healthcare Conference

Nordic Nanovector ASA (OSE: NANOV), clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, ...

Dec 07, 2021, 01:56 ET Nordic Nanovector to present at 3rd Targeted Radiopharmaceutical Summit 2021

Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune...

Nov 30, 2021, 01:36 ET Nordic Nanovector R&D Day: Building Value from Betalutin® and a pipeline of broader therapeutic opportunities targeting CD37

Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune...

Nov 29, 2021, 02:35 ET Nordic Nanovector ASA: R&D Day to be virtual via live webcast only

Nordic Nanovector ASA (OSE: NANOV), a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives...

Nov 18, 2021, 05:44 ET Correction: Nordic Nanovector ASA: Invitation to attend R&D Day - clarification of CMO title

Nordic Nanovector ASA (OSE: NANOV), a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives...